DOCSLIB.ORG

Hiv Medicine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hiv Medicine HIV MEDICINE Published on behalf of the British HIV Association and the European AIDS Clinical Society Editors Brian Gazzard, UK claims for missing or damaged copies within six months of publication, within Jens Lundgren, Denmark our reasonable discretion and subject to availability. Back issues: Single issues from current and recent volumes are available at the Associate Editors current single issue price from [email protected]. Earlier issues may be obtained from Periodicals Service Company, 351 Fairview Avenue – Ste 300, José Gatell, Spain Hudson, NY 12534, USA. Margaret Johnson, UK Tel: +1 518 822-9300, Fax: +1 518 822-9305, Jürgen Rockstroh, Germany Email: [email protected] Georg Behrens, Germany HINARI: Access to this journal is available free online within institutions in the Caroline Sabin, UK developing world through the HINARI initiative with the WHO. For information, visit www.who.int/hinari/en/ Roger Paredes, Spain Wiley is a founding member of the UN-backed HINARI, AGORA, and OARE initiatives. They are now collectively known as Research4Life, making online Editorial Board scientific content available free or at nominal cost to researchers in developing Jane Anderson, UK Jeff Lazarus, Denmark countries. Please visit Wiley’s Content Access – Corporate Citizenship site: http:// Francisco Antunes, Portugal Adriano Lazzarin, Italy www.wiley.com/WileyCDA/Section/id-390082.html Jose Arribas, Spain Hermione Lyall, UK Jason Baker, USA Paddy Mallon, Dublin Georg Behrens, Germany Esteban Martinez, Spain Publisher and Business Correspondence Sanjay Bhagani, UK Catia Marzolini, Switzerland HIV Medicine is published by John Wiley & Sons Ltd: 9600 Jordi Blanch, Spain Gail Matthews, Australia Garsington Road, Oxford OX4 2DQ, UK. Tel: +44 (0)1865 776868, Fax: +44 Stéphane Blanche, France Tamyo Mbisa, UK (0)1865 714591. Blackwell Publishing was acquired by John Wiley & Sons in Marta Boffito, UK Frank Miedema, Netherlands February 2007. Ray Brettle, UK José M Miró, Spain Wiley’s Corporate Citizenship initiative seeks to address the environmental, Françoise Brun-Vézinet, France Amanda Mocroft, London social, economic, and ethical challenges faced in our business and which are Fiona Burns, UK Jean-Michel Molina, France important to our diverse stakeholder groups. Since launching the initiative, we have focused on sharing our content with those in need, enhancing community Alexandra Calmy, Switzerland Santiago Moreno, Spain David Chadwick, UK philanthropy, reducing our carbon impact, creating global guidelines and best Fiona Mulcahy, Ireland practices for paper use, establishing a vendor code of ethics, and engaging our Richard Chaisson, USA Robert Murphy, USA Duncan Churchill, UK colleagues and other stakeholders in our efforts. Follow our progress at www. Mark Nelson, UK wiley.com/go/citizenship. Bonaventura Clotet, Spain Cristiana Oprea, Romania Nathan Clumeck, Belgium Journal Customer Services: For ordering information, claims and any enquiry Chloe Orkin, UK Dominique Costagliola, France concerning your journal subscription please go to https://hub.wiley.com/ George Panos, Greece Antonella d’Arminio Monforte, Italy community/support/onlinelibrary or contact your nearest office. Deenan Pillay, UK E-mail: [email protected]; Tel: +1 781 388 8598 or Mark Danta, Australia Americas: +1 800 835 6770 (Toll free in the USA and Canada). Andrea de Luca, Rome Daniel Podzamczer, Spain Bruce Polsky, USA Europe, Middle East and Africa: E-mail: [email protected]; Joseph Eron, USA Tel: +44 (0) 1865 778315. Sarah Fidler, UK Frank Post, UK Anton Pozniak, UK Asia Pacific: E-mail: [email protected]; Tel: +65 6511 8000. Andrew Freedman, UK Japan: For Japanese speaking support, Email: [email protected]. Hans-Jacob Furrer, Switzerland François Raffi, France Peter Reiss, Netherlands Visit our Online Customer Get-Help available in 7 languages at Christoph Fux, Switzerland https://hub.wiley.com/community/support/onlinelibrary Pablo Rojo, Spain Carlo Giaquinto, Italy Advertising: Sarah Young, HIV Medicine advertising Yvonne Gilleece, UK J. Richard Smith, UK (email: [email protected]) Magnus Gisslen, Sweden Vincent Soriano, Spain Commercial reprints: Dean Martin Andrew Grulich, Australia Ann Sullivan, UK (email: [email protected]) Ravi Gupta, India Claire Thorne, UK Scott Hammer, USA Stefano Vella, Italy Copyright and Copying Graham Hart, UK Jaime Vera, UK HIV Medicine © 2019 British HIV Association. All rights reserved. No part of Andrzej Horban, Poland Laura Waters, UK this publication may be reproduced, stored or transmitted in any form or Rusi Jaspal, UK Ed Wilkins, UK by any means without the prior permission in writing from the copyright Christine Katlama, France Alan Winston, UK holder. Authorization to copy items for internal and personal use is granted Peter Kelleher, UK Linda Wittkop, France by the copyright holder for libraries and other users registered with their local Justina Kowalska, Poland Robin Wood, Cape Town Reproduction Rights Organisation (RRO), e.g. Copyright Clearance Center (CCC), Ken Kunisaki, USA 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to Karine Lacombe, France other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for republication, for creating new collective works Editorial Office or for resale. Permissions for such reuse can be obtained using the RightsLink Editorial Director: Ann O'Mahony “Request Permissions” link on Wiley Online Library. Special requests should be Wiley Blackwell addressed to: [email protected] 9600 Garsington Road Oxford, OX4 2DQ, UK OnlineOpen Fax: +44 1865 714 591 HIV Medicine accepts articles for Open Access publication. Please visit http:// E-mail: [email protected] olabout.wiley.com/WileyCDA/Section/id-828081.html for further information about OnlineOpen. Production Editor Disclaimer John Marlou De Guzman (e-mail: [email protected]) The Publisher, the British HIV Association, the European AIDS Clinical Society and the Editors cannot be held responsible for errors or any consequences Aims and Scope arising from the use of information contained in this journal; the views and HIV Medicine aims to provide an alternative outlet for publication of opinions expressed do not necessarily reflect those of the Publisher, the British international research papers in the field of HIV Medicine, embracing clinical, HIV Association, the European AIDS Clinical Society and the Editors, neither pharmacological, epidemiological, ethical, preclinical and does the publication of advertisements constitute any endorsement by the in vitro studies. In addition, the journal will commission reviews and Publisher, the British HIV Association, the European AIDS Clinical Society and other feature articles. It will focus on evidence-based medicine as the mainstay Editors of the products advertised. of successful management of HIV and AIDS. ISSN 1464-2662 (Print) ISSN 1468-1293 (Online) Information for Subscribers For submission instructions, subscription and all other HIV Medicine is published in 10 issues per year. Institutional subscription prices information visit: www.hivmedicinejournal.com for 2019 are: Print & Online: US$2820 (US), US$3289 (Rest of World), €1940 (Europe), £1530 (UK). Prices are exclusive of tax. Asia-Pacific GST, Canadian Note to NIH Grantees GST/HST and European VAT will be applied at the appropriate rates. For more Pursuant to NIH mandate, Wiley Blackwell will post the accepted version information on current tax rates, please go to https://onlinelibrary.wiley.com/ of contributions authored by NIH grant-holders to PubMed Central upon library-info/products/price-lists/payment. The price includes online access to the acceptance. This accepted version will be made publicly available 12 months current and all online back files to January 1st 2015, where available. For other after publication. For further information, see www.wiley.com/go/nihmandate. pricing options, including access information and terms and conditions, please HIV MEDICINE (1464-2662) is published monthly except June and December. visit www.wileyonlinelibrary.com/access. US mailing agent: Mercury Media Processing, LLC 1850 Elizabeth Avenue, Suite #C, Rahway, NJ 07065 USA. Periodical postage paid at Rahway, NJ. Delivery Terms and Legal Title POSTMASTER: Send all address changes to HIV MEDICINE, John Wiley & Sons Where the subscription price includes print issues and delivery is to the Inc., C/O The Sheridan Press, PO Box 465, Hanover, PA 17331 USA. recipient’s address, delivery terms are Delivered at Place (DAP); the recipient is Typeset by Scientific Publishing Services (P) Ltd, responsible for paying any import duty or taxes. Title to all issues transfers Free and printed in the UK by Hobbs the Printer Ltd. of Board (FOB) our shipping point, freight prepaid. We will endeavour to fulfil hhiv_v20_s5_issueinfo.inddiv_v20_s5_issueinfo.indd 1 33/15/2019/15/2019 11:02:2411:02:24 AMAM HIV MEDICINE Volume 20, Supplement 5, April 2019 Abstracts of the 25th Annual Conference of the British HIV Association (BHIVA) Bournemouth, UK 2-5 April 2019 Contents Oral Abstracts O1–O6 Oral Research Presentations Session 1 3–5 O7–O15 Oral Research Presentations Session 2 5–9 O16–O24 Oral Research Presentations Session 3 9–13 O25–O30 Oral Research Presentations Session 4 13–15 Poster Abstracts P1–P21 Antiretrovirals: Efficacy, Interactions and Pharmacokinetics 16–24 P22–P25 Basic
Load more

Recommended publications
  • Sunday, November 7, 2021
    SUNDAY, NOVEMBER 7, 2021 PRE-CONFERENCE SESSIONS TBA 9:00 AM – 10:30 AM TBA TBA 10:30 AM - Noon TBA Noon - 1:00 PM Lunch OPENING REMARKS 1:00 PM - 1:15 PM Welcome to Adherence 2021 1:15 PM - 1:20 PM Break KEYNOTE ADDRESS Making Up for Lost Time: Critical Steps to Regain Momentum in HIV Prevention and Treatment 1:20 PM - 1:50 PM Meg Doherty, World Health Organization, Geneva, Switzerland* 1:50 PM - 1:55 PM Break HIV TREATMENT ADHERENCE Moderator : Jessica Haberer, Massachussetts General Hospital* and Jean Bisimwa Nachega, University of Pittsbur State-of-the-Art: A Review of Long-Acting Antivirals for HIV Treatment from an Adherence Perspective Susan Swindells, Nebraska AIDS Education Training Center, Omaha, NE, USA* Paradigm Shift: Asssessing Acceptability and Creating Demand for Long-Acting and Extended Release Formulations for HIV Treatment 1:55 PM - 3:10 PM Delivette Castor, Columbia University, New York, NY, USA* Antiretroviral Drug Resistance: Managing the Clinical Challenges of Long-Lasting Drug Concentrations Charlie Flexner, Johns Hopkins University, Baltimore, MD, USA* Discussion (15 minutes) 3:10 PM - 3:40 PM Break IMPLEMENTATION SCIENCE Moderator : Elvin Geng, Washington University of St. Louis* and Juliet Iwelunmor, Saint Louis University* Reaching Youth through Crowd Sourcing Juliet Iwelunmor, Saint Louis University, St. Louis, MO, USA COVID-19 and HIV Services: Disruptive Thinking for Disruptive Times 3:40 PM - 4:55 PM Matt Golden, University of Washington, Seattle, WA, USA Renewing Commitment to Equity in the HIV Response Lisa Bowleg, George Washington University, Washington, DC, USA Discussion (15 minutes) 4:55 PM - 5:00 PM Break THREE TOP-RATED ABSTRACTS 5:00 PM - 6:00 PM 6:00 PM Adjourn MONDAY, NOVEMBER 8, 2021 GARY S.
    [Show full text]
  • Are We Standing in Our Own Way on the Path to a Cure for HIV/AIDS
    PROFILE Are we standing in our own way on the path to a cure for HIV/AIDS lthough there are many reasons to celebrate the life-extending benefits from antiretroviral Atherapeutics (ART) for HIV/AIDS and the ability to chronically manage patients’ disease for decades, the majority of people around the world living with the virus do not have access to ART and those that do, have over decades developed life-threatening side effects. Our inability to identify a cure to HIV lies not only in the as-of- yet failure of the medical research community to identify and develop appropriate means of ridding the body of the virus but also government and industrial policies that promote public opinion exclusively focused on chronic management scenarios instead of broadly exploring innovation for cure. “An inconvenient truth” (Davis Guggenheim) mates of the magnitude of the global forced government policy for early epidemic. As the majority of Ameri - and expanded access to experimental There are approximately 37 million cans are not rountinely tested for HIV, drugs, the medical community and people living with HIV and 39 million the virus can go years without being society are struggling with the fact have died of AIDS-related diseases diagnosed in an HIV positive person. that we are barely managing the HIV since the start of the epidemic in 1981. With these statistics it is no wonder epidemic and AIDS crisis. For years we As of March 2015, only 15 million that every day an estimated 5,600 have been locked into thinking of people have access to treatments for people globally become newly infected solutions in terms of a chronic disease HIV.
    [Show full text]
  • Pathways to an HIV Cure: Tools for Community and Clinicians AIDS 2020: Virtual Pre-Conference 1 – 3 July
    Pathways to an HIV cure: tools for community and clinicians AIDS 2020: Virtual Pre-Conference 1 – 3 July WEDNESDAY 1 JULY 2020 7am PDT/ 10am EDT/ 4pm CEST & SAST/ 10pm CST/ midnight AEST 45’ Opening Welcome and Introduction Session Semi live Sharon Lewin, The Doherty Institute, The University of Melbourne, Australia Steve Deeks, UCSF, United States Keynote HIV cure strategies relevant to resource-limited settings Thumbi Ndung’u, Africa Health Research Institute, South Africa Community A glass half full: changing attitudes and values to achieve opening an HIV cure Michael Louella, defeatHIV CAB, United States 7.45am PDT/ 10.45am EDT/ 4.45pm CEST & SAST/ 10.45pm CST/ 00.45am AEST (+1d) 45’ Session 1 Advancing the HIV cure field and debunking myths and misconceptions On demand Chair Jessica Salzwedel, AVAC, United States Invited Top 5 myths and misconceptions speakers Advocacy-for-Cure grantees: Philister Adhiambo, Kenya Medical Research Institute, Kenya Owen Mulenga, Treatment Advocacy and Literacy Campaign, Zambia Josephine Nabukenya, MUJHU, Uganda Top 10 advances in laboratory research Lillian Cohn, Chan Zuckerberg Biohub, United States Top 10 advances in clinical research and social sciences Katharine J. Bar, Penn Centre for AIDS Research, United States THURSDAY 2 JULY 2020 6am PDT/ 9am EDT/ 3pm CEST & SAST/ 9pm CST/ 11pm AEST 45’ Session 2 Challenges of clinical trials in cure Semi live Moderator Richard Jefferys, TAG, United States Panelists Analytical Treatment Interruptions in HIV Cure clinical trials - community and clinician perspectives
    [Show full text]
  • FTC London Conference 2019 Report
    SEPTEMBER 9-11, 2019 CONFERENCE REPORT SPONSORED BY: IN PARTNERSHIP WITH: GLOBAL NETWORK OF PEOPLE LIVING WITH HIV LONDON FAST-TRACK CITIES 2019 CONFERENCE REPORT Contents INTRODUCTION . 2 Conference Framework . 4 Conference Report Structure . 4 LEADERSHIP IN ACTION . 5 A Tale of Three Fast-Track Cities . 5 London . 5 Nairobi City County . 7 New York City . 9 Projecting and Monitoring 90-90-90 . 13 Modeling Impact and Effectiveness . 15 Unite as Leaders . 16 PLACING PEOPLE AT THE CENTER . 17 Addressing Stigma . 18 Promoting U=U . 18 Addressing Stigma in Key Populations . 19 Risk, Vulnerability, and Transmission . 21 Violence against Adolescent Girls and Young Women . 21 Mental Health and Substance Use . 23 Aging with HIV . 24 Migration . 25 Injection Drug Use . 25 Prioritizing Quality of Life . 26 Community-Led Responses . 28 INNOVATIONS IN HIV TESTING, ART, AND PREP . 31 Innovations in HIV Testing . 31 HIV Self-Testing . 31 HIVcheck .jp Project . 31 Click-and-Collect . 32 Provider-Initiated HIV Testing . 33 Innovations in ART and ART Delivery . 33 RAPID . 34 Crescent Care Start Initiative . 35 1917 Clinic Fast-Track . 35 Rapid Start . 36 H-Team . 37 Innovations in HIV PrEP . 38 Technology and ART . 38 ADDRESSING COMORBIDITIES . 39 Tuberculosis . 39 Viral Hepatitis . 40 Other STIs beyond HIV . 41 CONCLUSION . 42 Acknowledgements . 45 i FAST-TRACK CITIES 2019 | SEPTEMBER 9-11, 2019 | BARBICAN CENTRE, LONDON LONDON FAST-TRACK CITIES 2019 CONFERENCE REPORT DEVELOPMENT OF THE FAST-TRACK CITIES 2019 CONFERENCE REPORT WAS SPONSORED BY: INTRODUCTION INTRODUCTION Since the Joint United Nations Programme on HIV/AIDS (UNAIDS) convened high-level stakeholders in December 2013 to plot a roadmap towards expanding access to HIV testing and treatment with the aim of blunting the course of the HIV epidemic, there has been a growing sense of commitment and optimism by governments, non-governmental organizations, funders, and community leaders that ending AIDS as a public health threat by 2030 may be feasible .
    [Show full text]
  • HIV/AIDS and Cancer Cure: Is It the Same Battle?
    HIV/AIDS and Cancer cure: Is it the same battle? Monsef Benkirane Molecular Virology Laboratory [email protected] IAS HIV Cure & Cancer Forum Paris, France www.iasociety.org Dynamic of imatinib-treated Chronic Myeloid Leukemia Mature cancer cells Highly divinding Cancer Stem cells www.iasociety.org Persistence and resistance are theBarriers to Cure HIV/AIDS Cancer Latent provirus Quiescent / slow-cycling Quiescent/ slow-cycling Long-lived Long-lived Indefinite proliferative potential Non sensitive to ART Enhanced repair capacity Not visible to the immune system highly resistant to DNA HIV-specific CD8 T cell response damage/Tolerance decreases with cART Enhanced checkpoint kinase expression drug efflux transporter Renewed by dedifferentiation of proliferating cancer HIV/AIDS and cancer are Residual diseases Although their molecular bases are different, similar cure strategies are being developed www.iasociety.org which cure and how to achieve it? Two main strategies are being pursued Eradication, which will require a complete elimination of infected cells, for which the Berlin patient represents a proof of concept. Considering the Boston patients, eradication will require elimination of HIV infected cells and replacement with HIV resistant cells. Remission: HIV controllers and the VISCONTI patients suggest that remission is achievable. This strategy should include monitoring of inflammatory and procoagulant indices. – Find and diminish size of the reservoir (LRAs, bNAbs, CAR-T cell) – Reduce seeding of latent pool with early/more ART – Reverse latency (LRAs, TLR7) – Increase HIV-specific immune function (vaccines or anti PD-L1) – Reduce immune activation – Gene therapy targeting the virus and the host – Allogeneic stem cell transplantation Combination therapy may be necessary While proof-of-concepts are there, we still have to gain important knowledge to achieve HIV eradication or remission Strategies to eradicate latent reservoirs.
    [Show full text]
  • Aidsimpact 2009 Programme
    1 Tuesday # Title Type Times Room Chairs SIDACTION, Tsodilo Vincent Douris, 1 An international measure of Quality of Life specific to PW HIV Satellite 10.00-13:00 B4 Veronica Noseda Tsodilo 2 Ethics of Clinical Research Satellite 10:00-13:00 Sidaction B1+2 Tsodilo 3 HIV considerations in Botswana Satellite 13:00-14:00 Sheila Tlou B1+2 Rosemary Building capacity for HIV/AIDS prevention trials in Africa: Strategies for Serondela 4 Satellite 10:00-12:00 Musonda, meeting a multi-dimensional challenge 3+4 Robert Geneau HSRC, Serondela 46 HIV in South Africa: A Turning Tide Among Teenagers? Satellite 12:00-14:00 Olive Shisana, 3+4 Linda Richter Tsodilo Simon Rosser, 47 Are gay communities dying Satellite 13:00-14:00 B4 William West Sheila Tlou, 5 Opening Ceremony Plenary 14:00-15:00Tsodilo C Batho C. Molomo 5.1OPENING CEREMONY - 14:00-14:05--National Anthem led by NACA Choi 14:05-14:10--Welcome remarks by Prof. Sheila Tlou, Co-Chair, Local Organising Committee 14:10-14:15--Remarks by Prof. Lorraine Sherr, AIDS Impact 14:15-14:20--Remarks Ms. Regina Lesole , Activist, Ms. Stigma-Free 2006 14:20-14:30--Song by NACA choir 5.2Mark Stirling Keynote address - Global HIV Challenges 2 Lorraine Sherr, 6 HIV state of the Art Plenary 15:30-18:00Tsodilo C Pepe Catalan 6.1Olive Shisana HIV in the disabled population: are we doing our part? 6.2Chloe Orkin Anti-retroviral therapy in 2009: what have we learned? 6.3Gita Ramjee HIV Prevention Overview 6.4Bruno Spire Quality of Life and HIV- ANRS Plenary 6.5John De Wit Gay Men 6.6Elly Katabira International AIDS
    [Show full text]
  • Study Protocol
    RIVER Protocol Version 5.0 20-Oct-2016 GENERAL INFORMATION This document was constructed using the MRC CTU Protocol Template Version 3.0. The MRC CTU endorses the Standard Protocol Items: Recommendations For Interventional Trials (SPIRIT) initiative. It describes the RIVER trial, co-ordinated by the Medical Research Council (MRC) Clinical Trials Unit at UCL (herein referred to as MRC CTU), and provides information about procedures for entering participants into it. The protocol should not be used as an aide-memoire or guide for the treatment of other participants. Every care has been taken in drafting this protocol, but corrections or amendments may be necessary. These will be circulated to the registered investigators in the trial, but sites entering participants for the first time are advised to contact RIVER Co-ordinating Centre at, MRC CTU, to confirm they have the most up-to-date version. COMPLIANCE The trial will be conducted in compliance with the approved protocol, the Declaration of Helsinki 1996, the principles of Good Clinical Practice (GCP), Commission Directive 2005/28/EC with the implementation in national legislation in the UK by Statutory Instrument 2004/1031 and subsequent amendments, the UK Data Protection Act (DPA number: Z6364106), and the National Health Service (NHS) Research Governance Framework for Health and Social Care (RGF). SPONSOR Imperial College London is the trial sponsor and has delegated responsibility for the overall management of the RIVER trial to the MRC CTU (RIVER Co-ordinating Centre). Queries relating to Imperial sponsorship of this trial should be addressed to the chief investigator via the Imperial Joint Research Compliance Office.
    [Show full text]
  • Boston March 4-7, 2018 Program and Conference Information
    Program and Conference Information Conference on Retroviruses and Opportunistic Infections Boston March 4-7, 2018 General Information CONTENTS Information General CROI FOUNDATION ...........................................................2 IAS–USA.......................................................................2 CROI 2018 PROGRAM COMMITTEE.........................................3 Scientific Program Committee .........................................3 Community Liaison Subcommittee .....................................5 EXTERNAL REVIEWERS . 6 SCHOLARSHIP AWARDEES ..................................................8 New Investigator Awardees.................................................8 International Investigator Awardees .......................................12 Community Educator Awardees............................................12 CONTINUING MEDICAL EDUCATION ......................................13 GENERAL INFORMATION . .15 Overview .................................................................15 Conference Support .......................................................15 Americans With Disabilities Act ............................................15 Emergency Services . .15 Embargo Policies and Social Media ....................................16 Welcome Reception .......................................................16 Meals.....................................................................16 Overflow Accommodations for Oral Sessions................................17 Mobile App ...............................................................17
    [Show full text]
  • Aidsimpact 2019 Draft Preliminary Programme
    4/16/2019 AIDSImpact AIDSImpact 2019 Draft Preliminary Programme Date Name Type Room Chairs 1 Monday 29th Opening Ceremony Plenary Syon 09:00 - Ballroom 10:00 2 Monday 29th Plenary Monday Plenary Syon 10:00 - 11:00 Ballroom “Alone we can do so little – together we can do so much”: bringing together the fields of biomedical and social sciences to enhance research programmes. (/abstracts/-LcVe5o7HzYXsvawSlzy) Caroline Sabin PrEP, biopolitics and biosociality: the unequal unfolding of biomedical HIV prevention (/abstracts/- LbaevTjutv6xBg-ruvA) Martin Holt 3 Monday 29th Community Dialogues Parallel Astor 11:30 - 12:30 www.aidsimpact.com 1/57 4/16/2019 AIDSImpact Date Name Type Room Chairs South African adolescent girls’ and young women’s narratives of communication with and support from parents and teachers: implications for sexual and reproductive health decisions (/abstracts/- LZtCv6dXuEhYZ5V5V8n) Zoe Duby, Kim Jonas, Kealeboga Maruping, Ashleigh LoVette, Caroline Kuo, Catherine Mathews The embodied relationality of blood-borne viruses: How families matter in the context of a stigmatised viral infection (/abstracts/-LZqqpIxbkjOKRBI0o8y) Asha Persson, Christy Newman, Myra Hamilton, Joanne Bryant, kylie valentine, Kerryn Drysdale, Rebecca Gray A support for autonomy for people living with HIV in West Guina: health and associative professionals’ discourses and visions on a complex phenomenon. (/abstracts/-LZfTrHBB_l_aYW52RT1) Anne-Sophie Petit, Nikos Kalampalikis, Marie Préau Adherence and retention in a community-based trial testing PrEP
    [Show full text]
  • Croi 2021 Program Committee
    General Information CONTENTS WELCOME . 2 General Information General Information OVERVIEW . 2 CONTINUING MEDICAL EDUCATION . 3 CONFERENCE SUPPORT . 4 VIRTUAL PLATFORM . 5 ON-DEMAND CONTENT AND WEBCASTS . 5 CONFERENCE SCHEDULE AT A GLANCE . 6 PRECONFERENCE SESSIONS . 9 LIVE PLENARY, ORAL, AND INTERACTIVE SESSIONS, AND ON-DEMAND SYMPOSIA BY DAY . 11 SCIENCE SPOTLIGHTS™ . 47 SCIENCE SPOTLIGHT™ SESSIONS BY CATEGORY . 109 CROI FOUNDATION . 112 IAS–USA . 112 CROI 2021 PROGRAM COMMITTEE . 113 Scientific Program Committee . 113 Community Liaison Subcommittee . 113 Former Members . 113 EXTERNAL REVIEWERS . .114 SCHOLARSHIP AWARDEES . 114 AFFILIATED OR PROXIMATE ACTIVITIES . 114 EMBARGO POLICIES AND SOCIAL MEDIA . 115 CONFERENCE ETIQUETTE . 115 ABSTRACT PROCESS Scientific Categories . 116 Abstract Content . 117 Presenter Responsibilities . 117 Abstract Review Process . 117 Statistics for Abstracts . 117 Abstracts Related to SARS-CoV-2 and Special Study Populations . 117. INDEX OF SPECIAL STUDY POPULATIONS . 118 INDEX OF PRESENTING AUTHORS . .122 . Version 9 .0 | Last Update on March 8, 2021 Printed in the United States of America . © Copyright 2021 CROI Foundation/IAS–USA . All rights reserved . ISBN #978-1-7320053-4-1 vCROI 2021 1 General Information WELCOME TO vCROI 2021 Welcome to vCROI 2021! The COVID-19 pandemic has changed the world for all of us in so many ways . Over the past year, we have had to put some of our HIV research on hold, learned to do our research in different ways using different tools, to communicate with each other in virtual formats, and to apply the many lessons in HIV research, care, and community advocacy to addressing the COVID-19 pandemic . Scientists and community stakeholders who have long been engaged in the endeavor to end the epidemic of HIV have pivoted to support and inform the unprecedented progress made in battle against SARS-CoV-2 .
    [Show full text]
  • (Rftca) Accelerates a Global Cure for Aids with License of Chromocell’S Proprietary Cell Engineering Technology
    RESEARCH FOUNDATION TO CURE AIDS (RFTCA) ACCELERATES A GLOBAL CURE FOR AIDS WITH LICENSE OF CHROMOCELL’S PROPRIETARY CELL ENGINEERING TECHNOLOGY • The Chromovertâ Technology platform provides an opportunity to create a scalable cell therapy cure for HIV/AIDS by enabling the purification of sufficient numbers of curative cells following the use of other biotechnologies already demonstrated to engineer cells that mimic natural biological resistance to HIV/AIDS; • With this technology, RFTCA will establish a new and charitable non-for-profit research incubator hub in order to research, develop and commercialize a safe and scalable cure for all those in need, regardless of ability to pay; • Chromovert Technology was invented at The Rockefeller University by Kambiz Shekdar, Ph.D., and is pioneered and owned by Chromocell Corporation, a life sciences company that was spun-out of the university. September 4, 2019 – NEW YORK, NY. – Research Foundation to Cure AIDS (RFTCA) has obtained a worldwide license to biotechnology known as Chromovertâ Technology, to research, develop and commercialize a cure for HIV/AIDS. This is the first and only case of an IRS Code § 501(c)3 not-for-profit organization holding rights to biotechnology with the promise to cure AIDS. RFTCA’s mission is to develop an AIDS cure and to make it available and affordable to all of the 37 million people living with HIV/AIDS worldwide. The emphasis in the medical community, until recently, has been on containing the AIDS epidemic with treatment and prevention alone. But recent advances in stem cell biology and cellular engineering have created new opportunities that could lead to a global cure.
    [Show full text]
  • Editing a Cure
    MILESTONES infection and prompted further research into gene-based therapies to genome editing target HIV. Although genome editing had had been been proven efficient in rendering proven efficient T cells refractory to HIV infection, in rendering it was not until years later, in 2014, T cells that a team led by Pablo Tebas and Carl June at the University of refractory to Pennsylvania in Philadelphia showed HIV infection this could be done in infected Credit: Bloomberg/Rob Waters via Getty Images Getty via Bloomberg/Rob Waters Credit: individuals. The clinical trial enrolled 12 patients who were infused with autologous CD4+ T cells modified at the CCR5 locus by zinc-finger nucleases (ZFNs). The patients who stopped ART after cell transfusion exhibited slow viral rebound and proliferation of the modified T cells, MILESTONE 18 indicating enhanced control of the virus. Moreover, one study participant with no viral rebound Editing a cure during ART interruption was found to harbor a single mutated copy of CCR5 and after transfusion a large Timothy Ray Brown—also known transplantation and interruption of proportion of this patient’s T cells as the ‘Berlin patient’—is the only antiretroviral therapy (ART). were resistant to HIV. person ever to be cured of HIV. His Although at the time of transplant Together, these findings story and the research that followed Brown also carried HIV variants demonstrated that gene-targeting are intimately linked to the discovery, tropic for the CXCR4 chemokine approaches could provide a safer back in 1996, that homozygosity for receptor, Hütter reasoned that their and more practical approach than a CCR5 allele with a 32-base-pair numbers might have been too low to the risky and restrictive HSCT and deletion (delta32/delta32) renders allow reseeding of the new immune opened the door for ZFNs and some individuals resistant to system.
    [Show full text]